Form 4: Edwards Lifesciences Executive Szyman Reports Stock Transactions
SEC Form 4 Filing
Catherine M. Szyman, CVP at Edwards Lifesciences, reports stock transactions including the vesting of performance rights and related share disposals to cover tax obligations.
Summary
- Catherine M. Szyman, a CVP at Edwards Lifesciences, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- On May 3, 2024, 479 shares were disposed of at a price of $85.06.
- On May 4, 2024, 5,796 shares were acquired through the vesting of performance rights.
- Also on May 4, 2024, 3,442 shares were disposed of at a price of $85.25.
- Following these transactions, Szyman directly owns 45,576.4373 shares of Edwards Lifesciences.
- The transactions included the vesting of performance-based restricted stock units granted on May 4, 2021, with 117.11% of the target number of shares vesting.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are routine and reflect standard executive compensation practices. The vesting of performance rights suggests positive performance, but the disposals are likely for tax purposes.
Positives
- The vesting of performance rights indicates that performance goals were met, leading to the acquisition of 5,796 shares.
Industry Context
Executive stock transactions are a normal part of corporate governance and can reflect management's confidence in the company or personal financial planning.
Comparison to Industry Standards
- Executive compensation packages often include performance-based equity awards, aligning management's interests with those of shareholders.
- Vesting schedules and performance metrics vary across companies and industries, but three-year vesting periods are common.
- Companies like Medtronic and Abbott also utilize performance-based equity compensation for their executives.
Stakeholder Impact
- The vesting of performance rights aligns executive compensation with company performance, potentially benefiting shareholders.
- The transactions themselves have a minimal direct impact on other stakeholders.
Key Dates
| Date | Description |
|---|---|
| 05/04/2021 | Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. |
| 05/01/2024 | The Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024. |
| 05/03/2024 | Disposal of 479 shares of Common Stock at $85.06. |
| 05/04/2024 | Vesting of 5,796 shares of Common Stock from Performance Rights and disposal of 3,442 shares of Common Stock at $85.25. |
| 05/03/2028 | Expiration Date of Performance Rights. |
| 05/06/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.